The expression of ARHI in pT2a and pT2b stage gastric cancer and its clinical significance

  • Authors:
    • Wei Wang
    • Xian-Min Bu
    • Jian Wang
    • Ning Zhang
    • Cheng-Hai Zhao
  • View Affiliations

  • Published online on: March 15, 2012     https://doi.org/10.3892/or.2012.1727
  • Pages: 1953-1959
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

ARHI is a novel tumor suppressor gene located on chromosome 1p31. Downregulation of ARHI expression has been detected in many types of cancer. However, the effects of ARHI in gastric cancer remain unclear. The aim of this study was to identify the relationship between ARHI expression and gastric cancer clinicopathological features. In this study, 81 pT2 stage gastric cancer specimens were subclassified by pT2a and pT2b stage. ARHI mRNA and protein levels were evaluated by real-time PCR and western blot analysis, respectively. Methylation plays an important role in suppressor gene silencing. We utilized methylation-specific PCR to identify the status of CpG islands in the ARHI gene. We used immunohistochemistry to determine the expression of the protein and analyzed clinicopathological features. The levels of ARHI mRNA in gastric cancer were lower compared to normal tissues (P<0.01). Similarly, the levels of ARHI protein in the cancer specimens were lower (P<0.05). DNA hypermethylation was identified in 79.1% of gastric cancer specimens without ARHI expression. Immunohistochemistry results were significantly correlated with the pT2 category (P<0.05). The cumulative survival rate of patients with ARHI expression was significantly higher compared to those without ARHI expression (P<0.05). ARHI as a suppressor is not only an important factor in the pathogenesis of gastric cancer, but also a potential factor for tumor aggravation. ARHI expression in gastric cancer can be employed to indicate favorable prognosis for the disease.

Related Articles

Journal Cover

June 2012
Volume 27 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang W, Bu X, Wang J, Zhang N and Zhao C: The expression of ARHI in pT2a and pT2b stage gastric cancer and its clinical significance. Oncol Rep 27: 1953-1959, 2012.
APA
Wang, W., Bu, X., Wang, J., Zhang, N., & Zhao, C. (2012). The expression of ARHI in pT2a and pT2b stage gastric cancer and its clinical significance. Oncology Reports, 27, 1953-1959. https://doi.org/10.3892/or.2012.1727
MLA
Wang, W., Bu, X., Wang, J., Zhang, N., Zhao, C."The expression of ARHI in pT2a and pT2b stage gastric cancer and its clinical significance". Oncology Reports 27.6 (2012): 1953-1959.
Chicago
Wang, W., Bu, X., Wang, J., Zhang, N., Zhao, C."The expression of ARHI in pT2a and pT2b stage gastric cancer and its clinical significance". Oncology Reports 27, no. 6 (2012): 1953-1959. https://doi.org/10.3892/or.2012.1727